Valeant Pharma (VRX) Trades at New Lows Amid Ex-Executive Probe

October 31, 2016 3:59 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Valeant Pharma (NYSE: VRX) is trading at fresh 52-week lows following reports ex-CEO, Michael Pearson and ex.-CFO, Howard Schiller, are the focus of criminal probe related potential accounting fraud tied to the company's hidden Philidor Rx Services company.

Shares last traded down 12.4% to $17.83.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Short Sales, Trader Talk

Add Your Comment